70
Participants
Start Date
January 31, 2017
Primary Completion Date
January 9, 2018
Study Completion Date
January 9, 2018
ONO-4474
Placebo matching ONO-4474
Investigational Site, Aalborg
Investigational Site, Frederiksberg
Investigational Site 4504, Odense
Investigational Site, Balatonfüred
Investigational Site, Budapest
Investigational Site, Eger
Investigational Site, Kistarcsa
Investigational Site, Mezőkövesd
Investigational Site, Szolnok
Investigational Site 4808, Bialystok
Investigational Site 4818, Bialystok
Investigational Site 4819, Bialystok
Investigational Site, Elblag
Investigational Site, Gdynia
Investigational Site, Katowice
Investigational Site, Kielce
Investigational Site 4810, Krakow
Investigational Site 4812, Krakow
Investigational Site, Lublin
Investigational Site, Nadarzyn
Investigational Site, Poznan
Investigational Site, Siedlce
Investigational Site, Staszów
Investigational Site 4811, Warsaw
Investigational Site 4815, Warsaw
Investigational Site, Wroclaw
Investigational Site 4801, Zamość
Investigational Site 4816, Zamość
Investigational Site, A Coruña
Investigational Site 3406, Barcelona
Investigational Site 3407, Barcelona
Investigational Site 3402, Madrid
Investigational Site 3410, Madrid
Investigational Site, Móstoles
Investigational Site, Sabadell
Investigator Site, Santiago de Compostela
Investigational Site, Seville
Investigational site, Villajoyosa
Investigational Site, Barnsley
Investigational Site, Blackpool
Investigational Site 4401, Leeds
Investigational Site 4410, Leeds
Investigational Site, Liverpool
Investigational Site, Manchester
Investigational Site, Middlesex
Investigational Site, North Shields
Investigational Site, Romford
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY